D-0140-2017 Class II Terminated

Recalled by Sandoz Inc — Princeton, NJ

FDA drug recall D-0140-2017 was initiated by Sandoz Inc on Nov 9, 2016 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised. The recall status is terminated (terminated Oct 17, 2017). Affected quantity: 18,751 vials.

Recall details

Product Type
Drugs
Report Date
Nov 23, 2016
Initiation Date
Nov 9, 2016
Termination Date
Oct 17, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
18,751 vials

Product description

L-Cysteine Hydrochloride Injection, USP, 0.5 g/10 mL (50 mg/mL), 10 mL Single Dose Vial (NDC 66758-004-01), packaged in 10 x 10mL Vials per carton (NDC 66758-004-02), Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540.

Reason for recall

Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.

Distribution pattern

Nationwide throughout the USA

Code information

Lot #: 2081915, 2082015, 2082115, 2082815, 2083115, Exp 08/17; 2090115, Exp 09/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0140-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0140-2017. Report a data issue: hello@regdatalab.com.